NEW YORK (Reuters Health) - The bone-strengthening drug zoledronic acid not only reduces fracture risk in patients with cancer that has spread to the bones, it also improves ...
LOS ANGELES (Reuters) - In a study, Amgen Inc's experimental drug denosumab reduced the risk of osteoporosis and fracture in men with prostate cancer ...
NEW YORK (Reuters Health) - Pooled data from 44 studies indicate that the tyrosine kinase EGFR and HER2 inhibitor lapatinib exhibits low cardiotoxicity in cancer patients. ...
